Published in Blood Weekly, February 10th, 2000
3DP-4815 is being developed for the treatment of arterial and venous thrombosis. The Phase I trial will be a randomized, double-blind, placebo-controlled, rising dose study, involving up to 45 volunteers. The only oral anticoagulant currently marketed is warfarin (sold as Coumadin and various generic versions).
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.